Thus, notably, targeting STAT6 can specifically enhance the chemosensitization of ALL cells to Ara-C by boosting Ara-C-induced apoptosis; this implies that STAT6 targeting may prove as a novel modality to surmount Ara-C resistance in ALL. This evidence concerns the gene STAT6 and acute lymphoblastic leukemia.